Cargando…

Effectiveness and Safety of First-Line Pembrolizumab in Older Adults with PD-L1 Positive Non-Small Cell Lung Cancer: A Retrospective Cohort Study of the Alberta Immunotherapy Database

The emergence of immunotherapy revolutionized the treatment of non-small-cell-lung cancer (NSCLC), with multiple landmark clinical trials establishing the efficacy of these agents. However, many patients who receive immunotherapy in clinical practice would be considered clinical trial ineligible. On...

Descripción completa

Detalles Bibliográficos
Autores principales:	Grosjean, Heidi A. I., Dolter, Samantha, Meyers, Daniel E., Ding, Philip Q., Stukalin, Igor, Goutam, Siddhartha, Kong, Shiying, Chu, Quincy, Heng, Daniel Y. C., Bebb, D. Gwyn, Morris, Don G., Cheung, Winson Y., Pabani, Aliyah
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8534423/ https://www.ncbi.nlm.nih.gov/pubmed/34677275 http://dx.doi.org/10.3390/curroncol28050357

Ejemplares similares

Association of Immune-Related Adverse Events, Hospitalization, and Therapy Resumption With Survival Among Patients With Metastatic Melanoma Receiving Single-Agent or Combination Immunotherapy
por: Watson, Alexander S., et al.
Publicado: (2022)

Clinical Factors Associated with Long-Term Survival in Metastatic Melanoma Treated with Anti-PD1 Alone or in Combination with Ipilimumab
por: Goutam, Siddhartha, et al.
Publicado: (2022)

The Lung Immune Prognostic Index Discriminates Survival Outcomes in Patients with Solid Tumors Treated with Immune Checkpoint Inhibitors
por: Meyers, Daniel E., et al.
Publicado: (2019)

Evaluation of the modified immune prognostic index to prognosticate outcomes in metastatic uveal melanoma patients treated with immune checkpoint inhibitors
por: Sander, Michael S., et al.
Publicado: (2021)

A Real-World Evaluation of Atezolizumab Plus Platinum-Etoposide Chemotherapy in Patients With Extensive-Stage SCLC in Canada
por: Elegbede, Anifat A., et al.
Publicado: (2021)

Effectiveness of Immune Checkpoint Inhibitor with Anti-PD-1 Monotherapy or in Combination with Ipilimumab in Younger versus Older Adults with Advanced Melanoma
por: Woo, Taylor E., et al.
Publicado: (2023)

Real-World Management and Outcomes of Crizotinib-Treated ROS1-Rearranged NSCLC: A Retrospective Canadian Cohort
por: Gibson, Amanda J. W., et al.
Publicado: (2022)

Treatment-Free Survival After Nivolumab vs Pembrolizumab vs Nivolumab-Ipilimumab for Advanced Melanoma
por: Gupta, Mehul, et al.
Publicado: (2023)

A Comparison of Patients’ and Physicians’ Knowledge and Expectations Regarding Precision Oncology Tests
por: Dehar, Navdeep, et al.
Publicado: (2022)

Real-World Treatment Patterns and Effectiveness of Targeted and Immune Checkpoint Inhibitor-Based Systemic Therapy in BRAF Mutation-Positive NSCLC
por: Gibson, Amanda J.W., et al.
Publicado: (2023)

Real World Outcomes in Patients with Advanced Melanoma Treated in Alberta, Canada: A Time-Era Based Analysis
por: Rigo, Rodrigo, et al.
Publicado: (2021)

Development and Validation of a Prognostic Risk Model for Patients with Advanced Melanoma Treated with Immune Checkpoint Inhibitors
por: Stukalin, Igor, et al.
Publicado: (2023)

Impact of the COVID-19 pandemic on cancer diagnoses, stage and survival in Alberta
por: Heer, Emily, et al.
Publicado: (2023)

Real-World Use of Granulocyte-Colony Stimulating Factor in Patients with Breast Cancer from Alberta, Canada
por: Ding, Philip Q., et al.
Publicado: (2022)

Estimating the Impact of Delayed Access to Oncology Drugs on Patient Outcomes in Canada
por: Vanderpuye-Orgle, Jackie, et al.
Publicado: (2022)

Real-World Treatment Patterns, Clinical Outcomes, and Health Care Resource Utilization in Extensive-Stage Small Cell Lung Cancer in Canada
por: O’Sullivan, Dylan E., et al.
Publicado: (2021)

Understanding Real-World Treatment Patterns and Clinical Outcomes among Metastatic Melanoma Patients in Alberta, Canada
por: O’Sullivan, Dylan E., et al.
Publicado: (2023)

430 Patients with Prolonged (>10 days) Neutropenia Displayed Similar IFI Rates Regardless of Hematologic Diagnosis and Chemotherapy Status: A Challenge to Antifungal Prophylaxis Decisions
por: Saxinger, Lynora, et al.
Publicado: (2014)

Mortality and Resource Use Among Individuals With Chronic Kidney Disease or Cancer in Alberta, Canada, 2004-2015
por: Tonelli, Marcello, et al.
Publicado: (2022)

Eligibility of real-world patients with metastatic breast cancer for clinical trials
por: Batra, Atul, et al.
Publicado: (2020)

Understanding Treatment Patterns and Outcomes among Patients with De Novo Unresectable Locally Advanced or Metastatic Urothelial Cancer: A Population-Level Retrospective Analysis from Alberta, Canada
por: Alimohamed, Nimira, et al.
Publicado: (2022)

A Case of Bowen’s Disease and Small-Cell Lung Carcinoma: Long-Term Consequences of Chronic Arsenic Exposure in Chinese Traditional Medicine
por: Lee, Linda, et al.
Publicado: (2005)

The emerging role of nimotuzumab in the treatment of non-small cell lung cancer
por: Boland, William, et al.
Publicado: (2010)

Contemporary Treatment of Metastatic Renal Cell Carcinoma
por: Stukalin, Igor, et al.
Publicado: (2016)

Impact of pre-existing cardiovascular disease on treatment patterns and survival outcomes in patients with lung cancer
por: Batra, Atul, et al.
Publicado: (2020)

Correction: Combined poly-ADP ribose polymerase and ataxia-telangiectasia mutated/Rad3-related inhibition targets ataxia-telangiectasia mutated-deficient lung cancer cells
por: Jette, Nicholas R., et al.
Publicado: (2020)

Combined poly-ADP ribose polymerase and ataxia-telangiectasia mutated/Rad3-related inhibition targets ataxia-telangiectasia mutated-deficient lung cancer cells
por: Jette, Nicholas R., et al.
Publicado: (2019)

A Population-Based Study to Evaluate the Associations of Nodal Stage, Lymph Node Ratio and Log Odds of Positive Lymph Nodes with Survival in Patients with Small Bowel Adenocarcinoma
por: Batra, Atul, et al.
Publicado: (2022)

The effect of the COVID-19 pandemic on bariatric surgery delivery in Edmonton, Alberta: a single-centre experience
por: Abu-Omar, Nawaf, et al.
Publicado: (2021)

Understanding Characteristics, Treatment Patterns, and Clinical Outcomes for Individuals with Advanced or Recurrent Endometrial Cancer in Alberta, Canada: A Retrospective, Population-Based Cohort Study
por: Martins, Diana, et al.
Publicado: (2023)

Predicting PARP inhibitor sensitivity and resistance
por: Bebb, D. Gwyn, et al.
Publicado: (2012)

The Three P's: Parotid, PD-L1, and Pembrolizumab
por: Wiggins, Amanda, et al.
Publicado: (2019)

Investigation of Molecular Interactions Mechanism of Pembrolizumab and PD-1
por: Wang, Simiao, et al.
Publicado: (2023)

A Real-World Evidence Study Using Alberta-Population-Based Data to Describe Treatment Patterns for Metastatic Castration-Sensitive Prostate Cancer Patients (AWARENESS)
por: Karim, Safiya, et al.
Publicado: (2023)

Evolution of an invasive ductal carcinoma to a small cell carcinoma of the breast: A case report
por: Hussain, Marya, et al.
Publicado: (2022)

ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib()
por: Wang, Chen, et al.
Publicado: (2017)

PD-1-inhibitor pembrolizumab for treatment of progressive multifocal leukoencephalopathy
por: Möhn, Nora, et al.
Publicado: (2021)

Prevalence, Treatment Patterns, and Outcomes of Individuals with EGFR Positive Metastatic Non-Small Cell Lung Cancer in a Canadian Real-World Setting: A Comparison of Exon 19 Deletion, L858R, and Exon 20 Insertion EGFR Mutation Carriers
por: O’Sullivan, Dylan E., et al.
Publicado: (2022)

Symptoms and Experiences with Small Cell Lung Cancer: A Mixed Methods Study of Patients and Caregivers
por: Bebb, D. Gwyn, et al.
Publicado: (2023)

The Best of Alberta /
Publicado: (1987)

Cannot write session to /tmp/vufind_sessions/sess_d4gio7n1a5ckcr0engct3gpjfo